Amicus Therapeutics (FOLD) insider plans 75,000-share stock sale via Form 144

Rhea-AI Filing Summary

Amicus Therapeutics insider plans Form 144 stock sale. A person identified through a 10b5-1 sales plan for Bradley Campbell filed notice to sell 75,000 shares of Amicus Therapeutics common stock through Morgan Stanley Smith Barney on the NASDAQ. The planned sale has an aggregate market value of $1,074,750.00 based on the figures in the notice, versus 308,533,548 Amicus common shares outstanding.

The shares to be sold were acquired on 01/20/2026 by exercising stock options from the issuer for cash on the same date. The filing also lists prior sales under the same 10b5-1 sales plan over the past three months, including 70,426 shares sold on 12/15/2025 for $763,509.39 and other smaller blocks, all in Amicus common stock.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	75000	1074750.00	308533548	01/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/20/2026	Exercise of Stock Options	Issuer			75000	01/20/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales Plan for BRADLEY CAMPBELL 47 Hulfish Street Princeton NJ 08542	Common	12/15/2025	70426	763509.39
10b5-1 Sales Plan for BRADLEY CAMPBELL 47 Hulfish Street Princeton NJ 08542	Common	12/15/2025	7500	82500.00
10b5-1 Sales Plan for BRADLEY CAMPBELL 47 Hulfish Street Princeton NJ 08542	Common	12/01/2025	14587	146011.49
10b5-1 Sales Plan for BRADLEY CAMPBELL 47 Hulfish Street Princeton NJ 08542	Common	11/24/2025	14587	146522.04

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Amicus Therapeutics (FOLD) disclose?

The Form 144 discloses a planned sale of 75,000 shares of Amicus Therapeutics common stock, with an aggregate market value of $1,074,750.00, to be executed through Morgan Stanley Smith Barney on the NASDAQ.

How were the 75,000 Amicus (FOLD) shares in the Form 144 acquired?

The 75,000 common shares were acquired on 01/20/2026 through the exercise of stock options from the issuer, paid for in cash on the same date.

When is the planned sale date for the 75,000 Amicus (FOLD) shares?

The notice states an approximate date of sale of 01/20/2026 for the 75,000 Amicus Therapeutics common shares covered by this Form 144.

How many Amicus Therapeutics (FOLD) shares are outstanding according to the Form 144?

The filing lists 308,533,548 Amicus Therapeutics common shares as outstanding in connection with the planned 75,000-share sale.

What recent Amicus (FOLD) stock sales are disclosed for the past 3 months?

The notice lists prior sales under a 10b5-1 sales plan for Bradley Campbell, including 70,426 shares sold on 12/15/2025 for $763,509.39, and additional common share blocks sold on 12/15/2025, 12/01/2025, and 11/24/2025 with specified share amounts and gross proceeds.

What does the 10b5-1 reference mean in the Amicus (FOLD) Form 144?

The seller information is identified as a 10b5-1 Sales Plan for Bradley Campbell, indicating sales are made under a pre-arranged trading plan; by signing, the person represents they do not know any undisclosed material adverse information about the issuer as of the plan adoption or instruction date.